NCT04396717View on ClinicalTrials.gov

Safety Study of Pritumumab in Brain Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions
Malignant Primary Brain TumorsBrain Metastases, Adult
Interventions
BIOLOGICAL

Pritumumab

Pritumumab IgG1 human monoclonal antibody

Trial Locations (2)

92123

Sharp Memorial Hospital, San Diego

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors

Lead Sponsor

Nascent Biotech
All Listed Sponsors
collaborator

Hoag Memorial Hospital Presbyterian

OTHER

lead

Nascent Biotech

INDUSTRY

NCT04396717 - Safety Study of Pritumumab in Brain Cancer | Biotech Hunter | Biotech Hunter